Trial Profile
Evaluation of safety of the combination of high dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant for multiple myeloma: a clinical phase I study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms Keio-Mel-Bor-Phase-I
- 05 Feb 2014 New trial record